Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-969"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20100922.20.3-969"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Pharmacovigilance is the system used to monitor the safety of medicinal products after they have been authorised for public use. A total of 197 000 people die in the European Union every year due to adverse reactions to medicinal products. Achieving a good pharmacovigilance system, based on healthcare professionals, companies and patients themselves reporting any adverse reactions, is therefore a priority. The rules regulating the centralised procedure are set out in Regulation No 726/2044, which relates to new medicinal products or those that combat cancer, HIV or degenerative diseases, while the centralised system is provided for in the present directive. I therefore advocate strengthening cooperation on pharmacovigilance at EU level, which allows for a more comprehensive ‘pool’ of adverse drug reactions to be obtained, and avoids duplicate monitoring of the same adverse reactions in other Member States. I welcome the measures proposed to encourage healthcare professionals to voluntarily report adverse drug reactions to their competent authority. I would particularly like to highlight the creation of a web portal for each Member State (Article 106 of the directive), where all relevant information relating to medicinal products will be made available to everyone who wants to consult it. These national web portals will be linked to the European web portal, which will be managed by the European Medicines Agency (Article 26 of the regulation)."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples